TheScreener - Alibaba Health Information Technology Ltd. (00241) Due to a more favourable environment, ALIBABA HLTH.INFO.TECH. slightly increases to Slightly Negative

Report

TheScreener

EUR 14.32 For Business Accounts Only

Due to a more favourable environment, ALIBABA HLTH.INFO.TECH. slightly increases to Slightly Negative

ALIBABA HLTH.INFO.TECH. (HK), a company active in the Medical Equipment industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date April 1, 2022, the closing price was HKD 4.97 and its target price was estimated at HKD 3.06.

02/04/2022 1 EN

Underlying

Alibaba Health Information Technology Ltd.

Alibaba Health Information Technology is an investment holding company. Co. is primarily engaged in pharmaceutical e-commerce, medical services network business and the operation of product tracking platforms in the People's Republic of China. Co. operates in two business segments, namely the pharmaceutical e-commerce segment, which consists of operating the B2C pharmacy business, providing outsourced and value-added services to the Tmall Entities, centralized procurement and distribution business and other related services; and the product tracking platform segment provides system services of product identification, authentication and tracking.

See profile

BMG0171K1018 Hong Kong Stock Exchange Bermuda

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

UOB

Alibaba Health Information Technology (241 HK): 1HFY25: Results in line; expect strong earnings growth momentum in FY25-26.

1HFY25 revenue grew 10.2% yoy, while adjusted net profit surged 52.2% yoy, in line with our and consensus’ FY25 estimates. Ali Health guides double-digit revenue growth for FY25-26, with healthcare products and OTC drugs as key growth drivers. We expect robust adjusted net profit CAGR of 31% for FY25-27, on an improving product mix towards healthcare products, and continued synergies in the marketing business. Maintain BUY with a higher target price of HK$5.00.

November 15, 2024 November 15, 2024 1 EN

UOB

Greater China Daily: Friday, November 15, 2024

KEY HIGHLIGHTS Sector Automobile China’s PV insurance registrations grew 27% yoy but fell 17% mom and 11% wow during 4-10 Nov 24. Major carmakers saw a dip in insurance registrations in China last week. PEVs’ market share rose 1.8ppt wow to 54.1%. We conducted a detailed assessment of the impact of US tariffs on the companies under our coverage, as shown in the last page. We believe auto part manufacturers are more vulnerable than OEMs. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL, Fuyao, and Desay SV. Results Alibaba Health Information Technology (241 HK/BUY/HK$4.04/Target: HK$5.00) 1HFY...

November 15, 2024 November 15, 2024 1 EN

UOB

Regional Morning Notes - Friday, November 15, 2024

GREATER CHINA Sector Automobile: Weekly: PV sales dip wow while PEV market share increases. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL, Fuyao Glass and Desay SV. Results Alibaba Health Information Technology (241 HK/BUY/HK$4.04/Target: HK$5.00): 1HFY25: Results in line; expect strong earnings growth momentum in FY25-26. Geely Auto (175 HK/BUY/HK$13.90/Target: HK$23.00): 3Q24: Core earnings up 81% yoy and 29% qoq, beating estimates. Maintain BUY. Raise target price from HK$21.50 to HK$23.00. JD.com (9618 HK/BUY/HK$135.10/Target: HK$197.00): 3Q24: Solid earnings beat; key proxy for benefits f...

November 15, 2024 November 15, 2024 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Due to a more favourable environment, ALIBABA HLTH.INFO.TECH. slightly increases to Slightly Negative

Empowering Investors

Alibaba Health Information Technology (241 HK): 1HFY25: Results in line; expect strong earnings growth momentum in FY25-26.

Greater China Daily: Friday, November 15, 2024

Regional Morning Notes - Friday, November 15, 2024

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe